## FOLLOW-UP VISIT PACKET UNIFORM DATA SET (UDS) VERSION 4.0



## Form D1a: Clinical Syndrome

| ADRC: _   | PTID: F   | Examiner's   Examiner's  |      |  |  |  |
|---|---|--|------|--|--|--|
| Langua  | glish   |  |      |  |  |  |
|   | RUCTIONS: This form is to be completed by the clinician. For acrm D1a. Check only one box per question.   | dditional clarification and examples, see the UDS Coding Guide   | book |  |  |  |
| 1.  | Diagnosis method—responses in this form are based on diagonal $1$ Single clinician $2$ Formal consensus panel $3$   |  |      |  |  |  |
| Sect  | ion 1 – Level of impairment – Unimpaired co   | ognition/behavior, SCD, MCI/MBI, or dementia   |      |  |  |  |
| 2.  | <ol> <li>Does the participant have:         <ol> <li>Unimpaired cognition (e.g., cognitive performance and functional status (i.e., CDR) judged to be unimpaired)?</li> </ol> </li> <li>AND         <ol> <li>Unimpaired behavior (i.e., the participant does not exhibit behavior sufficient to diagnose MBI – see MBI section starting at Q7) or dementia due to FTLD or LBD and/or FTLD behavior and language domains=0?</li> <li>No (SKIP TO QUESTION 3) 1 Yes (CONTINUE TO QUESTION 2a)</li> </ol> </li> <li>Note: For those with longstanding cognitive impairment that does not represent a decline from their usual functioning, consider checking Question 5b for a diagnosis of "Cognitively Impaired, Not MCI/dementia".</li> </ol> |  |      |  |  |  |
| Subjective Cognitive Decline  |   |  |      |  |  |  |
| 2a. Does the participant report 1) significant concerns about changes in cognition AND 2) no neuropsychological evidence of decline AND 3) no functional decline?  □ 0 No (END FORM HERE) □ 1 Yes |   |  |      |  |  |  |
| 2   | <b>2b.</b> As a clinician, are you confident that the subjective cogistic clinically meaningful?  | gnitive decline 0 No (END FORM HERE) 1 Yes (END FORM HERE)   |      |  |  |  |
| Dementia criteria   |   |  |      |  |  |  |
| Partic  | irement #1: ipant has cognitive or behavioral (neuropsychiatric) toms that meet <u>all of the following criteria</u> :  | Requirement #2: Participant must have impairment in <u>one* or more</u> of the following domains:  |      |  |  |  |
| u     R     A     Ir  | nterfere with ability to function as before at work or at sual activities epresent a decline from previous levels of functioning are not explained by delirium or major psychiatric disorder include cognitive impairment detected and diagnosed inrough a combination of: 1) history-taking; 2) objective ssessment (bedside or neuropsychological testing)  | <ul> <li>Impaired ability to acquire and remember new information</li> <li>Impaired reasoning and handling of complex tasks, poor judgment</li> <li>Impaired visuospatial abilities</li> <li>Impaired language functions</li> <li>Changes in personality, behavior, or comportment</li> <li>* In the event of single-domain impairment (e.g., language in PPA, behavior in bvFTD, visuospatial in posterior cortical atrophy, etc.), the participant must not fulfill criteria for MCI.</li> </ul> |      |  |  |  |
| 3.  | Does the participant meet criteria for dementia?  O No (CONTINUE TO QUESTION 4)  1 Yes (SKIF  | P TO QUESTION 6a)  |      |  |  |  |

naccmail@uw.edu ALZHEIMER'S COORDINATING naccdata.org

| Participant  | ID:   | Form date:                      | _ / /                   | Visit #:  |                  |  |  |
|--|---|---------------------------------|-------------------------|---|------------------|--|--|
|  |   |                                 |                         |   |                  |  |  |
| Section  | n 1 – Level of impairmen  | it                              |                         |   | continued        |  |  |
| MCI cor  | e clinical criteria   |                                 |                         |   |                  |  |  |
| Check all d  | riteria that apply in Q4.   |                                 |                         |   |                  |  |  |
|  | 4. Clinical concern about decline in cognition compared to participant's prior level of lifelong or usual cognitive function (e.g., based on input from participant, co-participant, and/or the clinician's judgment, CDR SB 0.5+, etc.)  1 Impairment in one or more cognitive domains, compared to participant's estimated prior level of lifelong or usual cognitive function, or supported by objective longitudinal neuropsychological evidence of decline  1 Largely preserved functional independence OR functional dependence that is not related to cognitive decline (e.g., based on clinical judgment) |                                 |                         |   |                  |  |  |
| Q4 are che   | criteria are checked, choose <b>1=Yes</b><br>ecked, with the exception of the thin<br>y the third MCI criteria is met in Q4,  | d MCI criteria <b>alone</b> , c | consider a diagnosis o  |   |                  |  |  |
| 4b.  | Does the participant meet all thr (amnestic or non-amnestic)?   | ee of the above crite           | ria for MCI             | O No (CONTINUE TO QUESTION)  1 Yes (SKIP TO QUESTION) |                  |  |  |
| Cogniti  | vely impaired, not MCI/den  | nentia                          |                         |   |                  |  |  |
|  | ose of the "Cognitively impaired, n   |                                 | tegory is to capture t  | those individuals with evider                         | nce of cognitive |  |  |
|  | nt or decline who do not meet for<br>applicable criteria for cognitive  |                                 | Ti/domontia in OE /     | using any rolovant data                               |                  |  |  |
| 5.   |   |                                 |                         |   |                  |  |  |
| If any of t  | ne criteria in Q5 are met choose <b>1</b> :   | <b>=Yes</b> for Q5b.            |                         |   |                  |  |  |
| 5b.  | Does the participant meet any credementia?  | riteria for cognitively         | impaired, not MCI/      | O No (SKIP TO QUESTION 1 Yes (SKIP TO QUESTION)       |                  |  |  |
| Affected   | d Domains – Dementia and  | MCI                             |                         |   |                  |  |  |
| Choose domains that are impaired at the current visit based on clinical judgment informed by clinical history and neuropsychological testing. <u>Select one or more</u> as <b>Impaired</b> ; all others will default to <b>unimpaired</b> in the NACC database.  |   |                                 |                         |   |                  |  |  |
| Note on <b>behavior changes</b> : For patients with <b>dementia</b> who have behavior changes, record the presence of behavioral changes here (not in the following MBI section) by marking Q6f as <b>Impaired</b> and skipping the MBI section ( <b>SKIP TO Q8</b> ). For behavioral changes in the context of an MCI (or as an isolated) symptom, consider a diagnosis of MBI in the next section. |   |                                 |                         |   |                  |  |  |
|  |   |                                 |                         |   | Impaired         |  |  |
| 6a.  | Memory  |                                 |                         |   | <u></u> 1        |  |  |
| 6b.  | Language  |                                 |                         |   | 1<br>            |  |  |
| 6с.  | Attention   |                                 |                         |   | <u></u> 1        |  |  |
| 6d.  | Executive   |                                 |                         |   | □1<br>□          |  |  |
| 6e.  | Visuospatial  |                                 | N.C. M.C.               |   | □1<br>□          |  |  |
| 6f.  | Behavioral (for participants with a   | aementia only; see ME           | sı tor MCI participants |   | □1<br>□          |  |  |
| 6g.  | Apraxia   |                                 |                         |   | <u></u> 1        |  |  |

| Sec   | tio  | n 1 – Level of impairment  |   | continued                     |  |  |  |
|---|--|--|---|-------------------------------|--|--|--|
| Milo  | l Be   | havioral Impairment (MBI) core clinical criteria   |   |                               |  |  |  |
| •   | <ul> <li>Participant, co-participant, or clinician identifies a change in the participant's affect, motivation, thought content, behavior, or personality that is clearly different from their usual affect, motivation, thought content, behavior, or personality</li> <li>Symptoms have been present at least intermittently for the last six months or longer</li> <li>Late onset (i.e., age &gt; ~50, unless early onset neurodegenerative syndrome is suspected)</li> </ul> |  |   |                               |  |  |  |
| 7.  |  |  | o (SKIP TO QUESTION 8) es (CONTINUE TO QUESTION | ON 7a)                        |  |  |  |
|   | (No  | BI affected domains — <u>Select one or more</u> affected domains ote: If "Yes" is indicated in any domain below, the participant should have a corresponding sympto<br>Symptoms, either from among the specific symptoms denoted there, or in "other")   | om checked on Form B9 — Clir<br>-               | nician Judgment               |  |  |  |
|   |  |  |   | No Yes                        |  |  |  |
|   | 7a.  | Motivation (e.g., apathy symptoms on Form B9)  |   | □0 □1                         |  |  |  |
|   | 7b.  | $Affective\ regulation\ (e.g.,\ anxiety,\ irritability,\ depression,\ and/or\ euphoria\ symptoms\ on\ Formula (e.g.,\ anxiety,\ irritability,\ depression,\ and/or\ euphoria\ symptoms\ on\ Formula (e.g.,\ anxiety,\ irritability,\ depression,\ and/or\ euphoria\ symptoms\ on\ Formula (e.g.,\ anxiety,\ irritability,\ depression,\ and/or\ euphoria\ symptoms\ on\ Formula (e.g.,\ anxiety,\ irritability,\ depression,\ and/or\ euphoria\ symptoms\ on\ Formula (e.g.,\ anxiety,\ irritability,\ depression,\ and/or\ euphoria\ symptoms\ on\ Formula (e.g.,\ anxiety,\ irritability,\ depression,\ and/or\ euphoria\ symptoms\ on\ Formula\ (e.g.,\ anxiety,\ irritability,\ depression,\ and/or\ euphoria\ symptoms\ on\ Formula\ (e.g.,\ anxiety,\ irritability,\ depression,\ and/or\ euphoria\ symptoms\ on\ Formula\ (e.g.,\ anxiety,\ anxiet$ | n B9)   | □ <sub>0</sub> □ <sub>1</sub> |  |  |  |
|   | 7c.  | Impulse control (e.g., obsessions/compulsions, personality change, and/or substance abuse s  | ymptoms on Form B9)                             | 0 1                           |  |  |  |
|   | 7d.  | Social appropriateness (e.g., disinhibition, personality change, and/or loss of empathy symplectic  | toms on Form B9)                                | □ <sub>0</sub> □ <sub>1</sub> |  |  |  |
|   | <b>7e.</b> Thought content/perception (e.g., delusions and/or hallucinations on Form B9)   |  |   |                               |  |  |  |
| Sec   | tio  | n 2 – Clinical syndrome  |   |                               |  |  |  |
| The purpose of Section 2 is to assign a predominant clinical syndrome to participants with dementia and, when appropriate MCI or MBI, using all available clinical, exam, and neuropsychiatric data. This should be done using clinical information and cognitive/neuropsychological testing, ideally without reference to biomarker data (which is incorporated into the Etiological Diagnoses section in Form D1b). This is not always possible and thus Q9 allows centers to record when biomarker data is known and may have influenced the clinical diagnosis. |  |  |   |                               |  |  |  |
| 8.  | No   | here a predominant clinical syndrome?<br>te that the participant may not meet any clinical criteria or may not have a predominant syndror<br>r instance, this is common for MCI and "impaired, not MCI"). In this case, select "No."   | o No (SKIP TO QU                                | JESTION 10)                   |  |  |  |
| Selec   | t the  | predominant syndrome as present; all others will default to Absent in the NACC d   | atabase.  | Present                       |  |  |  |
|   | 8a.  | Amnestic predominant syndrome  |   | □ 1                           |  |  |  |
|   | 8b.  | Dysexecutive predominant syndrome  |   | □ 1                           |  |  |  |
|   | 8c.  | Primary visual presentation (such as posterior cortical atrophy (PCA) syndrome)  |   | □ 1                           |  |  |  |
|   | 8d.  | Primary progressive aphasia (PPA) syndrome:  |   | □1                            |  |  |  |
|   | 80   | 1. If present, select one:  1 Semantic PPA 2 Logopenic PPA 3 Nonfluent/agrammatic PPA 5 Primary progressive apraxia of speech 4 PPA other/not otherwise specified  |   |                               |  |  |  |
|   | 8e.  | Behavioral variant frontotemporal (bvFTD) syndrome   |   | 1                             |  |  |  |
|   | 8f.  | Lewy body syndrome   |   | 1                             |  |  |  |
|   | 81   | 1. If present, select one:  1 Dementia with Lewy bodies  2 Parkinson's disease  3 Parkinson's disease dementia syndrome  |   |                               |  |  |  |
|   | 8g.  | Non-amnestic multidomain syndrome, not PCA, PPA, bvFTD, or DLB syndrome  |   |                               |  |  |  |
|   |  |  |   |                               |  |  |  |

Form date: \_\_\_ / \_\_\_ / \_\_\_ \_\_ \_\_

Visit #:

Participant ID:

| Sec   | tion  | 2 – Clinical syndrome   |          |      |         |              | continue              | ed  |
|---|---|---|----------|------|---------|--------------|-----------------------|-----|
|   |   |   |          |      |         |              | Prese                 | nt  |
| 8   | <b>3h.</b> Pr   | imary supranuclear palsy (PSP) syndrome   |          |      |         |              |                       |     |
|   | 8h1. If present, select one:  1 Richardson's syndrome criteria 2 Non-Richardson's |   |          |      |         |              |                       |     |
|   | <b>8i.</b> Tr   |   |          |      |         |              |                       | l   |
|   | <b>8j.</b> Co   |   |          |      |         |              |                       |     |
| 8   | 3k. M   | ultiple system atrophy (MSA) syndrome   |          |      |         |              |                       |     |
| 8k1. If present, select one:  1 MSA-predominant cerebellar ataxia (MSA-C) 2 MSA-predominant Parkinsonism (MSA-P) 3 MSA-predominant dysautonomia   |   |   |          |      |         |              |                       |     |
|   | <b>8I.</b> O  | ther (SPECIFY):   | <u> </u> |      |         |              |                       |     |
| 9.  |   | ate the source(s) of information used to assign the clint one or more as <b>Yes</b> ; all others will default to <b>No</b> in the | •        |      |         |              |                       |     |
|   |   |   |          |      |         |              | Yes                   |     |
| 9   | 9a. Cl  | inical information (history, CDR)   |          |      |         |              |                       |     |
| 9   | 9b. Cognitive testing   |   |          |      |         |              |                       |     |
| <b>9c.</b> Biomarkers (MRI, PET, CSF, plasma)   |   |   |          |      |         |              |                       |     |
| Section 3 – Primary or contributing non-neurodegenerative or non-CVD conditions   |   |   |          |      |         | ons          |                       |     |
| The purpose of Section 3 is to identify conditions or disorders that are present and potentially contributing to the clinical syndrome. This must be filled out for those with cognitive or behavioral impairment (i.e., MCI, MBI, dementia, etc.) Indicate whether a given condition is a primary, contributing, or non-contributing cause of the observed impairment, based on the clinician's best judgment. |   |   |          |      |         |              |                       |     |
| Select one or more condition(s) as <b>Present</b> ; if there are no primary or contributing non-neurodegenerative or non-CVD condition leave all conditions blank. All conditions left blank will default to <b>Absent</b> in the NACC database. <i>Only one diagnosis should be selected as 1 = Primary.</i>   |   |   |          |      |         |              |                       |     |
| *In order to diagnose a disorder, <b>DSM-5-TR criteria require</b> that symptoms cause clinically significant distress or impairment in social, occupational, or other important areas of functioning. For more guidance see the <b>UDS Coding Guidebook, Form D1a</b> .  |   |   |          |      |         |              |                       |     |
|   |   | Condition   | Present  |      | Primary | Contributing | Non-contribut         | ing |
| 10.   | Majo  | depressive disorder (DSM-5-TR criteria*)  | □ 1      | 10a. | □ 1     | $\square_2$  | 3                     |     |
| 11.   | Othe  | r specified depressive disorder (DSM-5-TR criteria*)  | □ 1      | 11a. | □ 1     | $\square_2$  | □ 3                   |     |
| 12.   | Bipol   | ar disorder (DSM-5-TR criteria*)  | □ 1      | 12a. | □ 1     | 2            | 3                     |     |
| 13.   | Schiz<br>criter   | ophrenia or other psychotic disorder (DSM-5-TR<br>ia*)  | □ 1      | 13a. | □ 1     | $\square_2$  | <b>□</b> <sub>3</sub> |     |
| 14.   | 1. Anxiety disorder (DSM-5-TR criteria*)  |   | □ 1      | 14a. | □ 1     | $\square_2$  | □ 3                   |     |
|   | lf  | present, (SPECIFY) (check all that apply):  |          |      |         |              |                       |     |
|   | <b>14b.</b> ☐ 1 Generalized anxiety disorder                                      |   |          |      |         |              |                       |     |
|   | 14c.  | <b>14c.</b>   |          |      |         |              |                       |     |
|   | 14d.  | 1 Obsessive-compulsive disorder (OCD)   |          |      |         |              |                       |     |
|   | 14e.  | 1 Other (SPECIFY):  |          |      |         |              |                       |     |
| 15.   | Post-   | traumatic stress disorder (PTSD)(DSM-5-TR criteria*)  | □ 1      | 15a. | □ 1     | $\square_2$  | 3                     |     |

Form date: \_\_\_ / \_\_\_ / \_\_\_ \_\_ \_\_

Participant ID:

| Participant ID: Form date: / / Visit #: |                 |            |   | 1 / 1 · / |
|---|-----------------|------------|---|-----------|
|   | Participant ID: | Form date: | / | Visit #:  |

| Section 3 – Primary or contributing non-degenerative or non-CVD conditions continued |  |                |      |           |                |                       |  |
|--|--|----------------|------|-----------|----------------|-----------------------|--|
|  | Condition  | Present        |      | Primary   | Contributing   | Non-contributing      |  |
| 16.  | Developmental neuropsychiatric disorders (e.g., autism spectrum disorder (ASD), attention-deficit hyperactivity disorder (ADHD), dyslexia)                                 | <b>□</b> 1     | 16a. | □ 1       | □ <sub>2</sub> | <b>□</b> 3            |  |
| 17.  | Delirium (DSM-5-TR criteria*)  | □1             | 17a. | □ 1       | $\square_2$    | 3                     |  |
| 18.  | Other psychiatric disorder (DSM-5-TR criteria*)  | □ 1            | 18a. | □ 1       | $\square_2$    | 3                     |  |
|  | 18b. If present, (SPECIFY):  |                |      |           |                |                       |  |
| 19.  | Traumatic brain injury<br>(Distinct from TES and CTE, which are documented as a<br>Clinical Syndrome and Etiologic Diagnosis, respectively)                                | □ 1            | 19a. | □ 1       | <b>□</b> 2     | <b>□</b> 3            |  |
| 20.  | Epilepsy   | 1              | 20a. | □ 1       | <u></u>        | 3                     |  |
| 21.  | Normal-pressure hydrocephalus  |                | 21a. | 1         | $\square_2$    | 3                     |  |
| 22.  | CNS Neoplasm   | □ 1            | 22a. | □ 1       | $\square_2$    | □3                    |  |
| 22   | 2b. If present, select one:  1 Benign 2 Malignant  |                |      |           |                |                       |  |
| 23.  | Human immunodeficiency virus (HIV) infection   | 1              | 23a. | □ 1       | $\square_2$    | 3                     |  |
| 24.  | Post COVID-19 cognitive impairment   | 1              | 24a. | □ 1       | $\square_2$    | 3                     |  |
| 25.  | Sleep apnea (i.e., obstructive, central, mixed or complex sleep apnea)   | □ <sub>1</sub> | 25a. | <u> </u>  | 2              | <b>□</b> 3            |  |
| 26.  | Cognitive impairment due to other neurologic, genetic, infectious conditions ( <i>not listed above</i> ), or systemic disease/medical illness (as indicated on Form A5/D2) | <b>□</b> 1     | 26a. | <u></u> 1 | <u></u>        | З                     |  |
| 26   | 6b. If present, (SPECIFY):   |                |      |           |                |                       |  |
| 27.  | Cognitive impairment due to alcohol use or abuse   | 1              | 27a. | □ 1       | _2             | 3                     |  |
| 28.  | Cognitive impairment due to substance use or abuse   | □ <sub>1</sub> | 28a. | □ 1       | $\square_2$    | □ 3                   |  |
| 29.  | Cognitive impairment due to medications  | □ 1            | 29a. | □ 1       | $\square_2$    | 3                     |  |
| 30.  | Cognitive impairment not otherwise specified (NOS)   | □ <sub>1</sub> | 30a. | □ 1       | $\square_2$    | <b>□</b> <sub>3</sub> |  |
| 30   | b. If present, (SPECIFY):  |                |      |           |                |                       |  |
| 31.  | Cognitive impairment not otherwise specified (NOS)   | □ 1            | 31a. | 1         | _2             | 3                     |  |
| 31b. If present, (SPECIFY):  |  |                |      |           |                |                       |  |
| 32.  | Cognitive impairment not otherwise specified (NOS)   | 1              | 32a. | □ 1       | _2             | 3                     |  |
| 37   | h If present (SPECIEV).  |                |      |           |                |                       |  |